Phase II Study of bevacizumab combined with chemotherapy (paclitaxel/carboplatin) as postoperative adjuvant therapy for cervical cancer
- Conditions
- Cervical cancer
- Registration Number
- JPRN-UMIN000029306
- Lead Sponsor
- niversity of the Ryukyus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 63
Not provided
1. Patients whose pathologically confirmed para aortic lymph node (PAN) metastasis. Patients who are suspected of PAN metastasis by preoperative imaging (CT with a short diameter of 10mm or more, suspicious metastasis with PET/CT, can't be registered if pathological negative is not confirmed. 2. Patients with active double cancer (synchronous double cancer and metachronous double cancer with disease-free period within 5 years). 3. Patient who have been treated with anti-VEGF and anti-VEGFR formulations. 4. Patients with symptomatic cerebrovascular disorders. 5. Patients with a high probability of bleeding due to congenital hemorrhagic diathesis, abnormal coagulation, etc. 6. Patients with severe cardiovascular disorders (such as poor control hypertension). 7. Patients with clinical symptoms of intestinal obstruction. 8. Patients with infection requiring systemic administration such as antibiotics, antivirals, antifungal drugs at registration. 9. Patients who received radiotherapy or chemotherapy before surgery.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method